Bedside stratification of patients according to CYP2C19*2 genotype

Rasa Karaliūtė; Olivija Gustienė; Nora Kupstytė; Daiva Ambrasienė; Vacis Tatarūnas

doi:10.6001/biologija.v64i2.3740

Rasa Karaliūtė
Olivija Gustienė
Nora Kupstytė
Daiva Ambrasienė
Vacis Tatarūnas

DOI: https://doi.org/10.6001/biologija.v64i2.3740

Keywords: stent thrombosis, CYP2C19, clopidogrel, gender, antiplatelets, genotype

Abstract

Objective. The task was to identify the defective CYP2C19*2 allele by using a novel fast-genotyping method in the patients having coronary artery disease who developed stent thrombosis or high on-treatment platelet reactivity. Materials and methods. A total of 35 patients were included in the study. All the patients were screened for CYP2C19*2 using Spartan RX CYP2C19 Assay Package. Results. CYP2C19*1*1 variant was found in 63%, *1*2 in 34%, *2*2 in 3% of patients. The distribution of genotypes was similar in men and women. Conclusions. By using the bedside technique, CYP2C19*2, which is responsible for a poorer effect of clopidogrel, might be identified in less than an hour.